ReviewFrontiers in immunology2026
Regulatory T cell therapy in solid organ transplantation: mechanisms, translational progress, and remaining barriers.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The long-term outcomes of solid organ transplantation are constrained by alloimmune rejection and the toxicities of lifelong immunosuppression; durable tolerance therefore remains an unmet goal. Regulatory T cells are central mediators of peripheral tolerance, capable of restraining cellular and antibody-mediated rejection while shaping the intragraft inflammatory and repair milieu, supporting a mechanistic rationale for immunosuppression minimization. This review integrates key mechanisms by which Tregs regulate transplant immunity and summarizes evidence for Treg-directed interventions from preclinical studies to early clinical translation across liver, kidney, heart, and lung transplantation. To address the persistent gap between biological promise and inconsistent clinical efficacy, we organize translational barriers using a failure-mode perspective across the therapeutic continuum, encompassing product attributes and manufacturing quality,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.